ADJUVANT INTRAPERITONEAL 5-FLUOROURACIL AND INTRAVENOUS LEUCOVORIN AFTER COLORECTAL-CANCER SURGERY - A RANDOMIZED PHASE-II PLACEBO-CONTROLLED STUDY

被引：47

作者：

GRAF, W

WESTLIN, JE

PAHLMAN, L

GLIMELIUS, B

机构：

[1] Department of Surgery, Akademiska Sjukhuset, Uppsala

[2] Department of Oncology, Akademiska Sjukhuset, Uppsala

来源：

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE | 1994年 / 9卷 / 01期

关键词：

D O I：

10.1007/BF00304298

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Fifty patients were randomized to receive adjuvant intraperitoneal 5-fluorouracil (5-FU, 500 mg/m2/day) and intravenous leucovorin (60 mg/m2/day) and 51 to receive placebo after curative surgery for colorectal cancer. Treatment started on the day after surgery and continued for 6 days. One case of stomatitis, one of leucopenia and one case of abnormal liver function tests were the only chemotherapy-related toxic effects. From the second day of treatment, pain during intraperitoneal infusions occurred more frequently in the 5-FU group, although statistical significance was only attained on day 2 (P < 0.05). The groups did not differ substantially regarding any other adverse effects, the incidence of surgical complications, second laparotomies, time from surgery to discharge, or premature treatment terminations. The postoperative course after intraperitoneal 5-FU and intravenous leucovorin was thus not more complicated than that in patients treated with placebo. The tolerance was acceptable and chemotherapy-related toxicity was rare. Thus important prerequisites exist for more widespread use of the present regimen in order to evaluate its impact on survival.

引用

页码：35 / 39

页数：5

共 29 条

[1]

Buyse M., Zeleniuch-Jacquotte A., Chalmers T.C., Adjuvant therapy of colorectal cancer. Why we still don't know, JAMA, 259, pp. 3571-3578, (1988)

[2]

Gray R., James R., Mossman J., Stenning S., AXIS — A suitable case for treatment, Br J Cancer, 63, pp. 841-845, (1991)

[3]

Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., Veeder M.H., Mailliard J.A., Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma, N Engl J Med, 322, pp. 352-358, (1990)

[4]

Taylor I., Machin D., Mullee M., Trotter G., Cooke T., West C., A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer, Br J Surg, 72, pp. 359-363, (1985)

[5]

Cunliffe W.J., Sugarbaker P.H., Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy, Br J Surg, 76, pp. 1082-1090, (1989)

[6]

Speyer J.L., Sugarbaker P.H., Collins J.M., Dedrick R.L., Klecker R.W., Myers C.E., Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans, Cancer Res, 41, pp. 1916-1922, (1981)

[7]

Miller A.B., Hoogstraten B., Staquet M., Winkler A., Reporting results of cancer treatment, Cancer, 47, pp. 207-214, (1981)

[8]

Goldman L.I., Lowe S., Al-Saleem T., Effect of fluorouracil on intestinal anastomoses in the rat, Arch Surg, 98, pp. 303-304, (1969)

[9]

Morris T., Retardation of healing of large bowel anastomoses by 5-fluorouracil, Australian NZJ Surg, 49, pp. 743-745, (1979)

[10]

De Roy van Zuidewijn D.B.W., Wobbes T., Hendriks T., Klompmakers A.A., De Boer H.H.M., The effect of antineoplastic agents on the healing of small intestinal anastomoses in the rat, Cancer, 58, pp. 62-66, (1986)

← 1 2 3 →